URMD -- Huge market potential Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Samuel J. Bennett who wrote (173)	12/12/1997 11:34:00 AM
From: TheCat	Read Replies (1) of 369

I am glad Goldman Sachs discovered the value of URMD because the rest of the market will recognize it in 1998. Most analysts have 1998 revenue figures at $15 million but they should be revised up to between $60 and $100million. URMD has $2 in cash and five FDA approved products. The two newest products (the Cavermap and the Breast Detection product) should have bigger market caps than the total value of URMD. In previous public statements The CEO of URMD (Jon Simon) said that he might spin off a couple of divisions to unlock their value. When this happens stock should soar. Other catalysts for the stock are more reimbursement announcements from HMO's. Right now the stock is being hurt by tax selling. For investors this is a great time to buy. Stock should bounce back in later this month and be poised for a break out year in 1998.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next